Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 11, 2021 08:00 ET | Source: 89bio, Inc.

89bio to Present at the Oppenheimer 31st Annual Healthcare Conference

SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
March 03, 2021 08:00 ET | Source: 89bio, Inc.

89bio to Participate in the H.C. Wainwright Global Life Sciences Conference

SAN FRANCISCO, March 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
February 24, 2021 08:00 ET | Source: 89bio, Inc.

89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference

SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
February 18, 2021 08:00 ET | Source: 89bio, Inc.

89bio to Present at the SVB Leerink 10ᵗʰ Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
January 05, 2021 08:00 ET | Source: 89bio, Inc.

89bio Provides Business Outlook for 2021

-Phase 2b NASH trial as part of a potential Phase 2b/3 program expected to initiate in 1H21- -Topline data from recently initiated NASH paired-biopsy, open-label histology cohort expected by YE21- ...
January 04, 2021 08:00 ET | Source: 89bio, Inc.

89bio to Participate in the H.C. Wainwright BioConnect 2021 Conference

SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
November 24, 2020 08:00 ET | Source: 89bio, Inc.

89bio To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
November 13, 2020 08:00 ET | Source: 89bio, Inc.

89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at AASLD’s The Liver Meeting® 2020

– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing – – Consistent results and baseline characteristics across biopsy confirmed and...
November 10, 2020 16:02 ET | Source: 89bio, Inc.

89bio Reports Third Quarter 2020 Financial Results and Provides Corporate Update

– Updated clinical data from BIO89-100’s Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting – – Planning to initiate the Phase 2b trial as part of the...
November 02, 2020 08:00 ET | Source: 89bio, Inc.

89bio To Present Data From Phase 1b/2a Study of BIO89-100 In NASH at AASLD’s The Liver Meeting® 2020

SAN FRANCISCO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...